• CNS Pharmaceuticals posted a net loss of $4.94 million for the quarter ended March 31, 2026, widening from $4.3 million a year earlier.
• Research and development expense rose to $3.54 million from $3.24 million, on higher professional expenses, headcount costs, drug manufacturing tied to TPI 287, and other items.
• General and administrative expense climbed to $1.43 million from $1.1 million, driven by higher legal and professional fees and insurance costs.
• Cash totaled $2.95 million at March 31, 2026, with a working capital deficit of $504,000.
• Strategy update in March pivoted focus toward developing therapies for serious diseases, including exploring out-licensing opportunities for legacy assets TPI 287 and Berubicin.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-003847), on May 14, 2026, and is solely responsible for the information contained therein.